Mabpharm Limited (HKG:2181)

Market Cap	2.10B +100.0%
Revenue (ttm)	464.53M +179.6%
Net Income	-30.11M
EPS	-0.01
Shares Out	4.12B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,000
Average Volume	128,100
Open	0.4900
Previous Close	0.5100
Day's Range	0.4900 - 0.5100
52-Week Range	0.2800 - 0.9400
Beta	1.05
RSI	46.50
Earnings Date	Mar 25, 2026

About Mabpharm

Mabpharm Limited, a biopharmaceutical company, engages in research, development, production, and commercialization of drugs and biosimilar for cancers and autoimmune diseases in the People’s Republic of China. The company offers CMAB007, a recombinant humanized anti-immunoglobulin E monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; and CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for the treatment...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 383
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2181

Financial Performance

In 2024, Mabpharm's revenue was 258.23 million, an increase of 196.27% compared to the previous year's 87.16 million. Losses were -127.95 million, -38.89% less than in 2023.

Financial numbers in CNY